Vicapsys Life Sciences, Inc. (VICP)
OTCMKTS · Delayed Price · Currency is USD
1.460
+0.470 (47.47%)
At close: Mar 30, 2026
Vicapsys Life Sciences Balance Sheet
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Assets
Fiscal Year | TTM | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|
Period Ending | Sep '24 Sep 30, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | Dec '19 Dec 31, 2019 |
Cash & Equivalents | 0.09 | 0.01 | 0.01 | 0.22 | 0 | 0.26 |
Cash & Short-Term Investments | 0.09 | 0.01 | 0.01 | 0.22 | 0 | 0.26 |
Cash Growth | 67.32% | -33.16% | -93.51% | 17023.33% | -99.52% | 206.00% |
Prepaid Expenses | - | 0.03 | 0.01 | 0.01 | - | - |
Other Current Assets | - | - | 0.05 | - | - | - |
Total Current Assets | 0.09 | 0.04 | 0.07 | 0.22 | 0 | 0.26 |
Other Intangible Assets | - | - | - | 0.37 | 0.4 | 0.43 |
Total Assets | 0.09 | 0.04 | 0.07 | 0.59 | 0.4 | 0.7 |
Liabilities
Fiscal Year | TTM | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|
Period Ending | Sep '24 Sep 30, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | Dec '19 Dec 31, 2019 |
Accounts Payable | 1.24 | 0.97 | 0.64 | 0.49 | 0.51 | 0.4 |
Accrued Expenses | 0.92 | 0.64 | 0.39 | 0.23 | 0.35 | - |
Short-Term Debt | 0.58 | 0.35 | - | - | - | - |
Total Current Liabilities | 2.74 | 1.97 | 1.02 | 0.72 | 0.85 | 0.4 |
Total Liabilities | 2.74 | 1.97 | 1.02 | 0.72 | 0.85 | 0.4 |
Shareholders' Equity
Fiscal Year | TTM | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|
Period Ending | Sep '24 Sep 30, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | Dec '19 Dec 31, 2019 |
Common Stock | 0.03 | 0.03 | 0.03 | 0.02 | 0.02 | 0.02 |
Additional Paid-In Capital | 14.37 | 14.34 | 14.14 | 13.98 | 13.42 | 13.4 |
Retained Earnings | -17.05 | -16.3 | -15.12 | -14.13 | -13.89 | -13.13 |
Comprehensive Income & Other | - | - | 0 | 0.01 | 0 | 0 |
Total Common Equity | -2.65 | -1.93 | -0.95 | -0.12 | -0.46 | 0.29 |
Shareholders' Equity | -2.65 | -1.93 | -0.95 | -0.12 | -0.45 | 0.3 |
Total Liabilities & Equity | 0.09 | 0.04 | 0.07 | 0.59 | 0.4 | 0.7 |
Additional Metrics
Fiscal Year | TTM | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|
Period Ending | Sep '24 Sep 30, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | Dec '19 Dec 31, 2019 |
Total Debt | 0.58 | 0.35 | - | - | - | - |
Net Cash (Debt) | -0.49 | -0.34 | 0.01 | 0.22 | 0 | 0.26 |
Net Cash Growth | - | - | -93.51% | 17023.33% | -99.52% | 206.00% |
Net Cash Per Share | -0.01 | -0.01 | 0.00 | 0.01 | 0.00 | 0.02 |
Filing Date Shares Outstanding | 32.37 | 32.07 | 31.19 | 30.16 | 30.11 | 17.48 |
Total Common Shares Outstanding | 32.37 | 32.07 | 31.19 | 19.75 | 17.48 | 17.48 |
Working Capital | -2.65 | -1.93 | -0.95 | -0.49 | -0.85 | -0.13 |
Book Value Per Share | -0.08 | -0.06 | -0.03 | -0.01 | -0.03 | 0.02 |
Tangible Book Value | -2.65 | -1.93 | -0.95 | -0.49 | -0.86 | -0.14 |
Tangible Book Value Per Share | -0.08 | -0.06 | -0.03 | -0.02 | -0.05 | -0.01 |